Recently, the list of selected candidates for the 2025 Shanghai "Oriental Talent Program" (Top Tier) was officially announced. Mr. Li Song, Vice President of Research and Development at ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange code: 01541.HK), was successfully selected for the program.

Mr. Li Song joined ImmuneOnco in December 2015. He served as Senior Director of R&D from January 2019 to January 2023, and has been Vice President of R&D since January 2023. As a leader of ImmuneOnco's R&D system, Mr. Li has long been dedicated to the research and development of innovative drugs in the field of cancer immunotherapy. He has been deeply involved in the formulation of R&D strategies and preclinical advancement of pipelines targeting CD47, PD-1/PD-L1, VEGF and other targets. His professional capabilities and contributions have been recognized with the "Outstanding Young Entrepreneur" Award in the Guangdong-Hong Kong-Macao Greater Bay Area. With a pragmatic work style and innovative thinking, Mr. Li leads the company's early-stage innovative drug research and development efforts, contributing to ImmuneOnco's path of steady innovation.

Being selected for the Shanghai "Oriental Talent Program" (Top Tier) is not only a high recognition of Mr. Li Song's personal scientific research capabilities and professional contributions, but also a full affirmation of ImmuneOnco's R&D innovation strength and talent pipeline development. The company will continue to build an international, high-level R&D team, accelerate the clinical development and commercialization of core products such as IMM01, and remain committed to its original mission of "developing first-class new drugs to benefit cancer patients."